Kantar Health Blog

  • Debbie Warner
    Value was an overarching theme at ASCO 2015 and has been a topic of ongoing focus, as have been the burgeoning pipeline of immunotherapy agents, with the recently launched PD-1 inhibitors, Opdivo® (nivolumab, Bristol Myers Squibb) and Keytruda® (pembrolizumab, Merck), being the highlights of ASCO 2015. Presenter Leonard Saltz, M.D. of Memorial Sloan Kettering praised the clinical value of an Opdivo + Keytruda combination as being “truly, truly remarkable,” but he added that with the combination costing nearly $300,000 (if continued for 11 months) “these drugs cost too much –unsustainable.” While Dr. Saltz is an unabashed critic of cancer drug prices, $300,000 would give most people pause.
    Continue Reading > | Go comment! | Share
  • Patricia Ensor
    One of the most debated aspects of the Affordable Care Act (ACA) is how the newly insured will use existing healthcare resources. Will they overwhelm emergency rooms? Will out-of-pocket costs continue to pose access barriers for these newly insured patients?
    Continue Reading > | Go comment! | Share
  • User Not Found
    There has been a fair amount of talk lately about the impact of payment reductions for cancer care services by 2%, and a reduction in reimbursement for buy and bill cancer drugs from ASP + 6% to ASP +4.3. So what is the impact of sequestration on oncology – is it a practice catastrophe, or just a reduction in profits?
    Continue Reading > | Go comment! | Share
  • User Not Found
    Pricing a drug is a hugely important aspect of pre-launch and launch planning as it can directly influence market share. Forecasting the dollar value of an oncology drug presents many challenges and caveats and takes into account price, duration of therapy, the eligible population, and market share of the eligible population.
    Continue Reading > | Go comment! | Share
  • User Not Found
    Most practices have weathered the storm of declining drug reimbursement. Patient volumes remain strong and reimbursement appears to be stable or positive. Practices generally report slow growth toward expansion and ongoing efficiency improvements. However, options for service diversification appear to be narrowing, with large practices likely to have added services requiring capital investment already. Overall, minor modifications to practice operations continue as practices actively explore new ways to remain competitive.
    Continue Reading > | Go comment! | Share
Page